Based on the molecular pathogenesis, the strategies to directly inhibit EGFR activity with small chemicals (e.g., gefitinib) and with biopharmaceuticals (e.g., cetuximab) should have worked as promising molecular‐targeted therapies paired with other chemotherapeutics and radiation therapy in cancer treatment.5, 6, 7, 8, 9, 10. This evidence concerns the gene EGFR and cancer.